Olfr1 (olfactory receptor family 1 subfamily E member 16) interacts with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) and are responsible for the recognition and G protein-mediated transduction of odorant signals. GPCRs are a large family of cell surface receptors that play crucial roles in cellular signal transduction. Their activation by various ligands, including hormones, neurotransmitters, and even sensory stimuli like odors, initiates a cascade of intracellular events. The inhibition of GPCR signaling is a significant area of pharmacological research due to the widespread roles of these receptors in physiological processes. Chemical inhibitors of GPCRs, such as the ones listed, operate through various mechanisms. Some, like propranolol, act as antagonists, blocking the receptor's active site and preventing the binding of natural ligands. Others, like aripiprazole, function as partial agonists or antagonists, modulating the receptor's activity rather than completely inhibiting it. These inhibitors often have high specificity, targeting distinct receptor subtypes, which is crucial for minimizing off-target effects.
The significance of GPCR inhibitors extends across multiple physiological systems. For instance, in the cardiovascular system, drugs like carvedilol and losartan are pivotal in managing conditions like hypertension and heart failure by modulating receptors involved in blood pressure regulation. In the central nervous system, compounds like risperidone and clozapine affect dopamine and serotonin receptors. Furthermore, their role in respiratory diseases is highlighted by agents like salmeterol and tiotropium bromide, which target receptors to alleviate asthma and COPD. Given the complexity and diversity of GPCR-mediated pathways, the development and application of these inhibitors require a deep understanding of receptor pharmacology and signaling mechanisms. While the direct application to Olfr1 is speculative, understanding the broader context of GPCR modulation provides a foundation for exploring potential indirect inhibitors or modulators for this specific receptor.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist, inhibiting GPCR signaling by blocking the action of epinephrine and norepinephrine. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
A non-selective beta-blocker and alpha-1 blocker, impacting GPCR-mediated signaling through multiple pathways. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
An alpha-2 adrenergic receptor antagonist, it inhibits GPCRs associated with adrenergic signaling. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
An angiotensin II receptor antagonist, it modulates GPCR activity related to blood pressure regulation. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
A serotonin 5-HT3 receptor antagonist, impacting GPCR signaling in the central nervous system and gastrointestinal tract. | ||||||
Risperidone | 106266-06-2 | sc-204881 sc-204881A sc-204881B sc-204881C | 10 mg 50 mg 1 g 5 g | $174.00 $719.00 $1020.00 $2040.00 | 1 | |
A dopamine D2 receptor antagonist, it also influences serotonin receptors, affecting multiple GPCR pathways. | ||||||
Aripiprazole | 129722-12-9 | sc-207300 sc-207300A sc-207300B | 100 mg 1 g 5 g | $179.00 $212.00 $1037.00 | 3 | |
A partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptor, modulating GPCR activity. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
A long-acting beta2-adrenergic agonist, affecting GPCR signaling in the respiratory system. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
An antagonist at various dopamine and serotonin receptors, demonstrating broad GPCR pathway modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
A competitive antagonist for the muscarinic acetylcholine receptors, a class of GPCRs. | ||||||